CompletedNCT00094926

A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolarity Who Have Frequent Mood Episodes.

Researchers compared Risperdal Consta and placebo, tracking side effects to assess safety in adults with bipolarity.

Medication studyAges 18–70

The study in practice

Understand this study

Researchers compared Risperdal Consta and placebo, tracking side effects to assess safety in adults with bipolarity.

This study was for people with bipolarity. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.

Study clarity

Study start dateMay 2004

Recruitment status: Completed
Enrollment listed in the registry: 275
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Not clearly listed
Age range: From 18 Years to 70 Years
Official registry ID: NCT00094926
Official title: Show the full official title
A Prospective, Randomized, Double-blind, Placebo-controlled Study of the Effectiveness and Safety of RISPERDAL CONSTA Augmentation in Adult Patients With Frequently-relapsing Bipolar Disorder

Completed

Locations not listed

FAQ

What did researchers investigate?

Researchers compared Risperdal Consta and placebo, tracking side effects to assess safety in adults with bipolarity.

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Risperdal Consta and placebo.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.